Article

Patients taking digoxin may develop color blindness

Author(s):

J.G. Lawrenson, PhD,Nancy Groves

London-Routine testing for color vision deficiency is not a reliable method to detect digoxin toxicity in patients taking the drug for heart failure or other cardiac problems, said J.G. Lawrenson, PhD.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
Related Content
Q&A: Kapil Mishra on radiation retinopathy in uveal melanoma
May 21st 2025

Q&A: Kapil Mishra on radiation retinopathy in uveal melanoma

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Viridian Therapeutics announces positive long-term durability data for veligrotug for the treatment of active thyroid eye disease
May 20th 2025

Viridian Therapeutics announces positive long-term durability data for veligrotug for the treatment of active thyroid eye disease

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Astigmatism in Hong Kong children increased substantially following COVID-19 era restrictions
May 20th 2025

Astigmatism in Hong Kong children increased substantially following COVID-19 era restrictions

Ashvattha reports positive phase 2 data for migaldendranib in retinal diseases
May 19th 2025

Ashvattha reports positive phase 2 data for migaldendranib in retinal diseases

© 2025 MJH Life Sciences

All rights reserved.